In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)’s ripple effects on plan risk and rebates, Most Favored Nation (MFN) policy proposals, and what it will take to reshore capacity while preserving competition and patient access.

Key Topics:


Generic Pricing Pressures: Purchaser consolidation, sterile injectables, margin squeeze, and exits.


Drug Shortage Economics: Quality investments, underpriced redundancy, lessons from saline disruptions.


Biosimilar Market Dynamics: Private-label payer programs, rebate tactics, chilling pipeline investment.


Inflation Reduction Act (IRA) and Coverage: Part D risk shift to plans, negotiation uncertainty, and Medicare access delays.


Tariffs and Reshoring: API onshoring realities, carve-outs to avoid shortages, resilient capacity building.

Opinions expressed are those of the speakers.

In this episode of the Vital Health Podcast, host <a href="https://www.linkedin.com/in/duane-schulthess-66ba39b7/?utm_source=chatgpt.com">Duane Schulthess</a> speaks with <a href="https://www.linkedin.com/in/john-murphy-iii-9b19ab1/">John Murphy</a>, President and CEO of the <a href="https://www.linkedin.com/company/accessiblemeds/?utm_source=chatgpt.com">Association for Accessible Medicines (AAM)</a>, to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)&rsquo;s ripple effects on plan risk and rebates, Most Favored Nation (MFN) policy proposals, and what it will take to reshore capacity while preserving competition and patient access.
Key Topics:
<ul data-start="675" data-end="1230">
<li data-start="675" data-end="790">
Generic Pricing Pressures: Purchaser consolidation, sterile injectables, margin squeeze, and exits.
</li>
<li data-start="791" data-end="899">
Drug Shortage Economics: Quality investments, underpriced redundancy, lessons from saline disruptions.
</li>
<li data-start="900" data-end="1009">
Biosimilar Market Dynamics: Private-label payer programs, rebate tactics, chilling pipeline investment.
</li>
<li data-start="1010" data-end="1116">
Inflation Reduction Act (IRA) and Coverage: Part D risk shift to plans, negotiation uncertainty, and Medicare access delays.
</li>
<li data-start="1117" data-end="1230">
Tariffs and Reshoring: API onshoring realities, carve-outs to avoid shortages, resilient capacity building.
</li>
</ul>
Opinions expressed are those of the speakers.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess is the CEO of Vital Transformation, host and producer of Vital Health Podcast.  Vital Transformation understands the implications of new medical procedures, technologies and regulations. We measure their impact upon treatment pathways and the biopharma innovation ecosystem in collaboration with health care professionals, researchers, and regulators. Through our web platform and client network, we are able to communicate our findings with international decision makers and stakeholders.

Duane Schulthess, Managing Director of Vital Tran…

Advertisement